Ho Geun Yoon

Title: The Innovative Contributions of Ho Geun Yoon

Introduction

Ho Geun Yoon is a notable inventor based in Goyang-si, South Korea. He has made significant contributions to the field of cancer research through his innovative work. His research focuses on the molecular mechanisms that influence cancer cell behavior, particularly through the study of specific proteins.

Latest Patents

Ho Geun Yoon holds a patent for the "Epitope of EPB41L5, and monoclonal antibody." This patent reveals the impact of the TGFβ/Smad3/EPB41L5 molecular mechanism on cancer cells. It has been discovered that high expression levels of EPB41L5 correlate with poor overall survival rates in cancer patients. This finding suggests that EPB41L5 could serve as a potential prognostic marker for cancer. The patent specifies an epitope of EPB41L5, allowing it to be recognized as an antigen. Furthermore, it relates to an antibody or a fragment that specifically binds to this epitope. The antibody described in the patent may be effectively utilized as a therapeutic agent for cancers associated with EPB41L5.

Career Highlights

Ho Geun Yoon is currently associated with Cellaster, Inc., where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential implications in improving cancer treatment outcomes.

Collaborations

Ho Geun Yoon collaborates with esteemed colleagues, including Kyung Chul Choi and Jae Ho Cheong. Their combined expertise contributes to the innovative research being conducted at Cellaster, Inc.

Conclusion

Ho Geun Yoon's contributions to cancer research through his patent on EPB41L5 highlight the importance of innovative approaches in understanding and treating cancer. His work exemplifies the potential of scientific research to impact patient outcomes positively.